Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Yamin Zhang, PhDa,b; Qiang Wang, MDa,b; Gavin P. Reynolds, PhDc; Weihua Yue, MD, PhDd,e; Wei Deng, MDa,b; Hao Yan, MDd,e; Liwen Tan, MDf; Chuanyue Wang, MD, PhDg; Guigang Yang, MDh; Tianlan Lu, MDd,e; Lifang Wang, MDd,e; Fuquan Zhang, MDi; Jianli Yang, MDj,k; Keqing Li, MDl; Luxian Lv, MDm; Qingrong Tan, MDn; Yinfei Li, MDa,b; Hua Yu, MDa,b; Hongyan Zhang, MD, PhDd,e; Xin Ma, MDg; Fude Yang, MDh; Lingjiang Li, MDf; Qi Chen, MDo; Wei Wei, MDa,b; Liansheng Zhao, MSca,b; Huiyao Wang, MMeda,b; Xiaojing Li, MDa,b; Wanjun Guo, MDa,b; Xun Hu, PhDp; Yang Tian, MSca,b; Hongyan Ren, MDa,b; Xiaohong Ma, MDa,b; Jeremy Coid, MDa,b; Dai Zhang, MD, PhDd,e; and Tao Li, MDa,b,*; for the Chinese Antipsychotics Pharmacogenomics Consortium

Published: March 24, 2020

Article Abstract

Objective: To compare longitudinal metabolic effects of 7 antipsychotics, including body mass index (BMI), waist circumference (WC), blood pressure (BP), glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C); to investigate risk factors for metabolic syndrome (MetS); and to make recommendations on frequency and timing of monitoring metabolic measurements.

Methods: This randomized, open-label, pharmacologic trial was conducted among patients with schizophrenia (DSM-IV) in 32 hospitals across China. Patients were randomly assigned to 7 groups and assessed at baseline, 2, 4, and 6 weeks. Linear mixed-effect models were used to assess changes of metabolic measures over time. Multivariable logistic regression analysis was performed to investigate the risk factors for MetS.

Results: In total, 2,550 (718 drug-naïve) of 2,774 patients finished the study between July 6, 2010, and November 30, 2011. We found significant (P < .05) changes for BMI, WC, TG, and LDL-C, with TG and LDL-C reaching a plateau. Interactions between baseline metabolic condition and changes over time were observed for BMI (χ2 = 43.11, P < .001), WC (χ2 = 36.34, P < .001), systolic BP (χ2 = 11.92, P = .002), glucose (χ2 = 6.09, P = .01), and TG (χ2 = 6.01, P = .01). Antipsychotics generally had greater adverse effects on patients who were initially screened as metabolically normal. After controlling for other associated factors, we found that antipsychotics resulted in differing risk for incident MetS, with a similar pattern to findings in other populations: olanzapine (odds ratio [OR] = 3.36, P < .001) > quetiapine (OR = 3.29, P < .001) > perphenazine (OR = 2.73, P = .007) > risperidone (OR = 2.21, P = .02) > aripiprazole (OR = 1.74, P = .15) ≈ haloperidol (OR = 1.75, P = .22) ≈ ziprasidone (OR = 1, reference).

Conclusions: Metabolic traits should be monitored frequently in early stages of antipsychotic treatment due to rapid and substantial changes. Clinicians should not assume low risk for patients with normal metabolic parameters at baseline.

Trial Registration: Chinese Clinical Trial Registry identifier: ChiCTR-TRC-10000934

Volume: 81

Quick Links: Metabolic Disorder , Side Effects-Medication

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...